KR20220039725A - 작용제의 세포 및 조직으로의 전달을 위한 신규 펩티드, 조성물 및 방법 - Google Patents

작용제의 세포 및 조직으로의 전달을 위한 신규 펩티드, 조성물 및 방법 Download PDF

Info

Publication number
KR20220039725A
KR20220039725A KR1020227003440A KR20227003440A KR20220039725A KR 20220039725 A KR20220039725 A KR 20220039725A KR 1020227003440 A KR1020227003440 A KR 1020227003440A KR 20227003440 A KR20227003440 A KR 20227003440A KR 20220039725 A KR20220039725 A KR 20220039725A
Authority
KR
South Korea
Prior art keywords
cell
peptide
nuc1
tissue
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227003440A
Other languages
English (en)
Korean (ko)
Inventor
라젠드라 쿠마르-싱
Original Assignee
트러스티즈 오브 터프츠 칼리지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 트러스티즈 오브 터프츠 칼리지 filed Critical 트러스티즈 오브 터프츠 칼리지
Publication of KR20220039725A publication Critical patent/KR20220039725A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020227003440A 2019-07-02 2020-07-02 작용제의 세포 및 조직으로의 전달을 위한 신규 펩티드, 조성물 및 방법 Pending KR20220039725A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962869831P 2019-07-02 2019-07-02
US62/869,831 2019-07-02
PCT/US2020/040720 WO2021034418A2 (en) 2019-07-02 2020-07-02 Novel peptide, compositions and method for delivery of agents into cells and tissues

Publications (1)

Publication Number Publication Date
KR20220039725A true KR20220039725A (ko) 2022-03-29

Family

ID=74659924

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227003440A Pending KR20220039725A (ko) 2019-07-02 2020-07-02 작용제의 세포 및 조직으로의 전달을 위한 신규 펩티드, 조성물 및 방법

Country Status (9)

Country Link
US (2) US11713337B2 (https=)
EP (1) EP3994151A4 (https=)
JP (1) JP7581264B2 (https=)
KR (1) KR20220039725A (https=)
CN (1) CN114555625B (https=)
AU (1) AU2020332268B2 (https=)
CA (1) CA3144963A1 (https=)
IL (1) IL289516A (https=)
WO (1) WO2021034418A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026005189A1 (ko) * 2024-06-27 2026-01-02 이엔셀 주식회사 안구 세포 또는 조직을 표적하는 펩타이드 및 이를 포함하는 바이러스 캡시드 단백질 및 바이러스 벡터

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3100276A1 (en) 2018-06-06 2019-12-12 Massachusetts Institute Of Technology Circular rna for translation in eukaryotic cells

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5211657A (en) * 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
DE19827457C1 (de) * 1998-06-19 2000-03-02 Medigene Ag Strukturprotein von AAV, seine Herstellung und Verwendung
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
JP3635462B2 (ja) * 2000-05-31 2005-04-06 国立医薬品食品衛生研究所長 アデノウイルスベクター
SE0301431D0 (sv) * 2003-05-19 2003-05-19 Dermagen Novel antimicrobial peptides
US8076295B2 (en) * 2007-04-17 2011-12-13 Nanotope, Inc. Peptide amphiphiles having improved solubility and methods of using same
AU2008295509A1 (en) * 2007-08-29 2009-03-12 Tufts University Methods of making and using a cell penetrating peptide for enhanced delivery of nucleic acids, proteins, drugs, and adenovirus to tissues and cells, and compositions and kits
EP2187907A2 (en) * 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Use of tyr-w-mif-1 and urocortin 2 as therapeutic agents
CN102869384B (zh) * 2009-06-22 2016-01-13 伯纳姆医学研究所 使用带有c-端元件的肽和蛋白质的方法和组合物
US20130158103A1 (en) * 2011-11-23 2013-06-20 The Curators Of The University Of Missouri Method of Tissue-Selective Targeted Gene Transfer
EP3076792B1 (en) * 2013-12-04 2020-11-11 Newleaf Symbiotics, Inc. Compositions and methods for improving lettuce production
US10316061B2 (en) * 2014-10-02 2019-06-11 Temple University Of The Commonwealth System Of Higher Education Synthesis of cell penetrating peptides for drug delivery and stem cell applications
CN108064229B (zh) * 2015-03-12 2021-12-28 三洋化成工业株式会社 蛋白质组合物的制造方法和蛋白质组合物
US9738687B2 (en) * 2015-04-10 2017-08-22 Feldan Bio Inc. Polypeptide-based shuttle agents for improving the transduction efficiency of polypeptide cargos to the cytosol of target eukaryotic cells, uses thereof, methods and kits relating to same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026005189A1 (ko) * 2024-06-27 2026-01-02 이엔셀 주식회사 안구 세포 또는 조직을 표적하는 펩타이드 및 이를 포함하는 바이러스 캡시드 단백질 및 바이러스 벡터

Also Published As

Publication number Publication date
US20230340024A1 (en) 2023-10-26
AU2020332268A1 (en) 2022-02-24
CN114555625A (zh) 2022-05-27
WO2021034418A2 (en) 2021-02-25
JP7581264B2 (ja) 2024-11-12
CN114555625B (zh) 2025-02-25
JP2022538903A (ja) 2022-09-06
WO2021034418A3 (en) 2021-04-01
AU2020332268B2 (en) 2025-04-24
US11713337B2 (en) 2023-08-01
EP3994151A2 (en) 2022-05-11
IL289516A (en) 2022-03-01
EP3994151A4 (en) 2023-07-19
US20220204562A1 (en) 2022-06-30
CA3144963A1 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
BR112021007221A2 (pt) proteínas inteínas e seus usos
CA2901439C (en) Peptides for use in the topical treatment of retinal neurodegenerative diseases, in particular in early stages of diabetic retinopathy and other retinal diseases in which neurodegeneration plays an essential role
US20120315256A1 (en) Use of transforming growth factor - beta 1 (tgf-b1) inhibitor peptides for the treatment of corneal fibrosis and/or haze
JP6640311B2 (ja) 軟骨細胞の細胞外基質由来ペプチド
US20230340024A1 (en) Novel peptide, compositions and method for delivery of agents into cells and tissues
Liu et al. siRNA silencing of gene expression in trabecular meshwork: RhoA siRNA reduces IOP in mice
EP3829621A1 (en) Engineered hemichannels, engineered vesicles, and uses thereof
Kumar et al. Cell-Penetrating chaperone Nuc1 for Small-and Large-Molecule delivery into retinal cells and tissues
US20160144055A1 (en) Gene therapy vector for treatment of steroid glaucoma
EA048046B1 (ru) Новый пептид, композиции и способ доставки агентов в клетки и ткани
WO2019133950A1 (en) Smad7 for treatment and prevention of posterior capsule opacification
KR102023827B1 (ko) 안구 건조증 질환의 치료 및/또는 예방을 위한 짧은 합성 펩티드의 용도
US20250177573A1 (en) Materials & Methods for Treatment of Macular Degeneration
CN113727990B (zh) 短合成肽及其治疗视网膜退化性疾病和/或组织损伤的用途
JP7495230B2 (ja) 処置方法および新規構築物
Read Non-Viral Gene Therapy for the Treatment of Retinal Degeneration

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000